Pharmacoepidemiological analysis: dynamics of availability of statins in Ukraine
DOI:
https://doi.org/10.24959/cphj.16.1383Keywords:
pharmacoeconomics, statins, pharmaceutical market, range of drugs, dynamics, coefficient of the solvency adequacyAbstract
Diseases of the circulatory system are the main cause of disability and premature death in Ukraine. A great number of RCTs and meta-analyses proved high preventive efficiency of statins to reduce the cardiovascular risk. The aim of the study is to analyze the dynamics of cost and availability of statin drugs in Ukraine in 2012-2015. Dynamics of the prices for some statin drugs was determined according to the data of the “Pharmstandard” system of “Morion” company. To assess availability of the statin therapy the coefficient of the solvency adequacy was used. According to the results of the study it has been found that at the pharmaceutical market of Ukraine there is an adequate range of statin drugs. During the period from 2012 to 2015 there was the positive dynamics of the market structure – increase in domestic drug production and its share in the market structure. From 2014 there was the increase in prices for the vast majority of drugs of the statin group of both domestic and foreign production – the average for the group was 42.1% and 101.4%, respectively. The dynamics of the solvency adequacy indicates decrease in availability of statin drugs for the Ukrainian consumers in the period from 2012 to 2015. Under these conditions the possibility of the primary and secondary prevention of CVD is provided by high economic availability of domestic generic drugs, which range over the past four years has increased by 38%. Measures in the healthcare system, contributing to increase availability and the amounts of statin use in Ukraine are needed.
References
Гандзюк В.А. // Укр. кардіол. журн. – 2014. – №3. – С. 45-52.
Гудзенко О.П., Козицька К.І. // Укр. мед. альманах. – 2009. – №5. – С. 63-67.
Державна служба статистики України [Електронний ресурс] – Режим доступу до сайту: http://www.ukrstat.gov.ua/
Дубенко O.E., Кульгейко B.B., Коваленко Д.П. и др. // Междунар. неврол. журн. – 2012. – №5 (51) – С. 162-168.
Котвицкая А.А., Лобова И.А. // Научные ведомости Белгородского государственного университета. Медицина. Фармация. – 2013. – №11 (154). – Вып. 22/2. – С. 32-38.
Немченко А.С., Ніколаєва Ю.Є. Аналіз коефіцієнту адекватності платоспроможності протипухлинних препаратів, що використовуються у хіміотерапії хронічних лейкозів // Менеджмент та маркетинг у складі сучасної економіки, науки, освіти, практики : матер. III міжнар. наук.-практ. Internet-конф., м. Харків, 26-27 берез. 2015 р. – Х. : НФаУ, 2015. – С. 310-311.
Программный комплекс «Аптека» компании «Морион» [Електронний ресурс] – Режим доступу до сайту: http://pharmbase.com.ua/poisk/.
Якушева Е.Н., Ушкалова Е.А. // Рос. мед.-биол. вестник им. акад. И.П.Павлова. – 2008. – №3. – С. 25-29.
Amarenco P., Labreuche J. // Lancet Neurol. – 2009. – Vol. 8. – P. 453-463.
Baigent C., Keech A., Kearney P.M. et al. // Lancet. – 2005. – Vol. 336 (9493). – P. 1267-1278.
Bellosta S., Ferri N., Paoletti R. et al. // Ann. Med. – 2000. – Vol. 32. – P. 164-176.
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials // Lancet. – 2015. – Vol. 385, Is. 9976. – P. 1397-1405.
Ford I., Murray H., McCowan C. et al. // Circulation. – 2016. – Vol. 133 (11). – P. 1073-1080. TableDistribution of statin drugs in accordance with the categories of availability by the coefficient of the solvency adequacy MNN Manufacturer Categories of availability 2012 (%) 2013 (%) 2014 (%) 2015 (%) Simvastatin domestic highly available Ca.s < 5% 77.8 100 100 100 medium available < 5%Ca.s < 15% 22.2 import highly available Ca.s < 5% 69.4 80.0 60.7 61.9 medium available < 5%Ca.s < 15% 30.6 20.0 39.3 38.1 Atorvastatin domestic highly available Ca.s < 5% 100.0 100.0 100.0 100.0 import Ca.s < 5% 90.7 91.5 80.0 69.7 medium available < 5%Ca.s < 15% 7.0 6.4 16.0 24.2 low available Ca.s > 15% 2.3 2.1 4.0 6.1 Rosuvastatin domestic highly available Ca.s < 5% 100.0 100.0 import highly available Ca.s < 5% 89.3 91.7 83.7 90.0 medium available < 5%Ca.s < 15% 10.7 8.3 16.3 10.0 КЛІНІЧНА ФАРМАЦІЯ. – 2016. – Т. 20, № 210 ISSN 1562-725X
Fox K., Alonso Garcia M., Ardissino D. et al. // Eur. Heart. J. – 2006. – Vol. 27. – P. 1341-1381.
Guidelines for ATC classification and DDD assignment. 16th edition / WHO Collaborating Centre for Drug Statistics Methodology. – Oslo, 2012. – 284 р.
Gutierrez J., Ramirez G., Rundek T. et al. // Arch. Intern. Med. – 2012. – Vol. 172. – P. 909-919.
Heintjes E.M., Penning-van Beest F.J., Plat A.W. et al. // Pharmacotherapy. – 2012. – Vol. 32, №7. – P. 631-641.
Introduction to drug utilization research / WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services // World Health Organization, 2003. – 48 р.
Jones P.H., Davidson M.H., Stain E.A. et al. // Am. J. Cardiol. – 2003. – Vol. 92, №2. – P. 152-160.
Law M.R., Wald N.J., Rudnicka A.R. // BMJ. – 2003. – Vol. 236. – P.1423-1426.
Luvai A., Mbagaya W., Hall A.S. et al. // Clin. Med. Insights Cardiol. – 2012. – Vol. 6. – P. 17-33.
Mills E.J., Rachlis B., Wu P. et al. // J. Am. Coll. Cardiol. – 2008. – Vol. 52 (22). – P. 1769-1781.
Mills E.J., Wu P., Chong G. et al. // Q. J. Med. – 2011. – Vol. 104. – P. 109-124.
Naci H., Brugts J., Ades T. // Circ. Cardiovasc. Qual. Outcomes. – 2013. – Vol. 6, №4. – Р. 390-399.
OECD Health Statistics 2015 Definitions, Sources and Methods [Електронний ресурс] – Режим доступу до сайту: http://www.oecd.org/health/health-data.htm
Pedersen T.R. // Circ. Res. – 2016. – Vol. 118, №4. – P. 721-731.
Prospective Study Collaboration Blood cholesterol and vascular mortality by age sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular death // Lancet. – 2007. – Vol. 370. – P. 1829-1833.
Reiner Ž., De Backer G., Fras Z. et al. // Atherosclerosis. – 2016. – Vol. 13 (246). – P. 243-250.
Roth L., Rombouts M., Schrijvers D.M. et al. // Vascul. Pharmacol. – 2016. – Jan 27. – Р. 50-58.
Rubba P., Marotta G., Gentile M. // Vasc. Health Risk Manag. – 2009. – Vol. 5. – P. 343-352.
Taylor F., Ward K., Moore N. et al. // Cochrane Database Syst. Rev. – 2013. – Vol. 31. – №1. – P. 36.
Ward S., Lloyd J.M., Pandor A. et al. // Health Technol. Assess. – 2007. – Vol. 11 (14). – P. 1-160.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
